Samsung Bioepis, Genentech settle patent dispute on breast cancer biosimilar: source
상태바
Samsung Bioepis, Genentech settle patent dispute on breast cancer biosimilar: source
  • Son Da-som
  • 승인 2019.07.04 10:16
  • 댓글 0
이 기사를 공유합니다

The agreement will allow Samsung Bioepis to distribute, market and sell the biosimilar Ontruzant in the United States, according to the source.

Ontruzant, the breast cancer treatment biosimilar referencing Roche's Herceptin, won approval from the U.S. Food and Drug Administration earlier this year.

Samsung Bioepis is a joint venture between Samsung BioLogics -- a biopharmaceutical unit of South Korea's top conglomerate Samsung Group -- and its U.S. partner Biogen Inc.

Biosimilars are defined by the FDA as products that are "highly similar to an already approved biological product" and have "no clinically meaningful differences in terms of safety and effectiveness from the reference product." (Yonhap)

Headquarters building of Samsung Bioepis Co.in Songdo, west of Seoul.

댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.
주요기사